SinoMab Bioscience Sets Out Board and Committee Structure

The latest announcement is out from SinoMab Bioscience Ltd. ( (HK:3681) ).

SinoMab BioScience Limited has announced the current composition of its board of directors, led by Executive Director Dr. Shui On Leung, who serves as both chairman and chief executive officer alongside a mix of non-executive and independent non-executive directors. The company also detailed the updated membership and leadership structure of its audit, remuneration and nomination committees, clarifying governance responsibilities that are important for investors’ oversight of management and board decision-making.

The strengthened committee disclosures, including chairperson roles held by Dr. Leung, Mr. Ping Cho Terence Hon and Dr. Chi Ming Lee, signal a continued focus on formal corporate governance arrangements as SinoMab advances its business. Clear delineation of board and committee functions is intended to support transparency, internal control and alignment with Hong Kong listing requirements, factors that can influence shareholder confidence and regulatory compliance as the company pursues its strategic objectives.

The most recent analyst rating on (HK:3681) stock is a Sell with a HK$1.50 price target. To see the full list of analyst forecasts on SinoMab Bioscience Ltd. stock, see the HK:3681 Stock Forecast page.

More about SinoMab Bioscience Ltd.

SinoMab BioScience Limited is a Hong Kong–incorporated biopharmaceutical company listed on the Main Board of the Stock Exchange of Hong Kong under stock code 3681. The company focuses on the research, development and commercialization of innovative biologic therapies, particularly targeting immune-related and other specialty disease areas in global and regional markets.

Average Trading Volume: 5,142,840

Technical Sentiment Signal: Buy

Current Market Cap: HK$2.42B

See more data about 3681 stock on TipRanks’ Stock Analysis page.